How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

887 results for

Rivastigmine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Pharmacological and Non-Pharmacological Interventions to Enhance Sleep in Mild Cognitive Impairment and Mild Alzheimer s Disease: A Systematic Review Full Text available with Trip Pro

– Insomnia (CBT-I), A Multi-Component Group Based Therapy, Phase Locked Loop Acoustic Stimulation, Melatonin, Donepezil, Galantamine, Rivastigmine, Tetrahydroaminoacridine and Continuous Positive Airway Pressure (CPAP). Psychotherapeutic approaches utilising adapted CBT-I achieved statistically significant improvements in the Pittsburgh Sleep Quality Index with one study reporting co-existent improved actigraphy variables. Melatonin significantly reduced sleep latency and sleep to wakefulness transitions

2020 Cold Spring Harbor Laboratory

142. Reabilitação Cognitiva em Pacientes com a Doença de Alzheimer: Revisão Sistemática / Cognitive Rehabilitation in Patients with Alzheimer's Disease: Systematic Review Full Text available with Trip Pro

: o que os enfermeiros sabem? Revista gaúcha de enfermagem, Porto Alegre, 32(2) 270-278, 2011. PUYVELDE, V.; METS, T. Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: A study in a real life population. Japan Geriatrics Society, Bruxelas, 11(3): 256–261, 2011. SANTORO, A., et al. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study. CNS Drugs, Bologna

2020 ID on line REVISTA DE PSICOLOGIA

144. Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine

and behavioural disturbances in dementia: carbamazepine (ESUOM40) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 18 of 21In 2006, NICE published a guideline on dementia: supporting people with dementia and their carers in health and social care (NICE guideline CG42), which has been incorporated into a NICE pathway. NICE guidance is also available on donepezil, galantamine, rivastigmine and memantine for the treatment

2015 National Institute for Health and Clinical Excellence - Advice

145. Dementia in Older People

but important part in management of dementia, providing symptomatic benefit with acetyl cholinesterase inhibitors (AChEI) (donepezil, rivastigmine and 8 galantamine) and memantine, which is a N- methyl-D-aspartate partial antagonist. AChEI have shown modest symptomatic improvement in 40-50% of people in cognitive function, global outcomes and activities of daily living. 61 Evidence suggests positive benefits for non-cognitive symptoms, especially apathy, depression and anxiety and improved function compared (...) with placebo. 62 Side effects include nausea, vomiting, diarrhoea, dizziness, weight loss and bradycardia. 63 Memantine is well tolerated, with main side- effects, including constipation, dizziness and headache and has a potential role in the management of agitation in more severe disease. In Australia and New Zealand, subsidised funding for AChEIs is only available for those with Alzheimer’s Disease. Restricted criteria are available for memantine in Australia and rivastigmine in New Zealand for those

2017 Australian and New Zealand Society for Geriatric Medicine

147. Physical therapy in patients with Alzheimer’s disease: a systematic review of randomized controlled clinical trials Full Text available with Trip Pro

evolved, with anticholinesterase drugs (donezepil, rivastigmine, epstatigmine, and galantamine) acting on the symptoms of the disease by improving the healthcare network. Complementing this therapy with rehabilitation could enhance the action of pharmacological treatment, leading to an improvement in cognitive performance, behavior, and quality of life . However, these studies are limited by short follow-up period, retrospective design, poorly defined controls, and small sample sizes. In our study

2019 Fisioterapia e Pesquisa

148. Systematic Review of Acupuncture Treatment for Mild Cognitive Impairment Full Text available with Trip Pro

[ ], identified by Petersen, a psychiatrist in the United States in 1966. A clinical study has shown that 44% of patients diagnosed with MCI developed dementia within 3 years [ ]. Thus, the need for treatment of MCI is important to reduce the potential progression to dementia. Currently there is no approved drug to treat MCI in Western medicine. Alzheimer's drugs such as donepezil, rivastigmine, and cholinesterase inhibitors, have been evaluated as potential treatments for MCI in a number of clinical trials

2019 Journal of Acupuncture Research

149. A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer’s disease Full Text available with Trip Pro

with donepezil, in adult patients diagnosed with moderate to severe AD, with disease severity determined by a specified assessment scale. Only complete economic assessments (cost-effectiveness analysis, cost-utility analysis or cost-benefit analysis) with the clear identification of comparators (placebo, no specific treatment, galantamine, rivastigmine or donepezil anticholinesterases or other types of non-pharmacological treatment) and measures of outcome, such as cost per year of life gained, cost per (...) , galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Technology appraisal guidance [TA217] [Internet]. London: NICE; 2018. [acesso em 08 ago. 2019]. Disponível em https://www.nice.org.uk/guidance/TA217 [ ] 21 Brasil. Ministério da Saúde. Portaria GM/MS nº 843, de 31 de outubro de 2002. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Doença de Alzheimer. Diário Oficial da União. 04 nov. 2002. [ ] 22 Costa RDF, Osório-de-Castro CGS, Silva RM, Maia AA, Ramos MCB, Caetano

2019 Revista Brasileira de Geriatria e Gerontologia

150. Management of Behavioural and Psychological Symptoms of Dementia (BPSD)

of cholinesterase inhibitor therapy for management of BPSD. In this review they 8 analysed 14 clinical trails examining the efficacy of donepezil, rivastigmine and galantamine for management of BPSD. In this review only three studies showed statistically significant and clinically modest benefit. They supported cholinesterase inhibitor therapy for management of BPSD in the absence of effective and safe alternative therapy. A systematic review by Henry and colleagues 99 and a Cochrane review by Seitz et al 100

2016 Australian and New Zealand Society for Geriatric Medicine

151. Clinical practice guidelines for dementia in Australia Full Text available with Trip Pro

that the person with dementia (or their carer[s] or family) make an appointment to see a dentist to conduct an assessment and formulate a long-term treatment plan. Acetylcholinesterase inhibitors and memantine are routinely prescribed for people with mild to moderate Alzheimer disease in order to delay functional decline, and the guidelines support their use. Based on recent evidence, the guidelines also state that any one of the three acetylcholinesterase inhibitors (donepezil, galantamine or rivastigmine (...) Education Services, Department of Health and Ageing Pharmaceutical Policy Branch, Ahmed R. Post market review: Pharmaceutical Benefits Scheme anti-dementia medicines to treat Alzheimer disease. Canberra: Department of Health, 2012. (accessed Jan 2016). Birks J, Craig D. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev 2006; (1): CD004746. Birks J, McGuinness B, Craig D. Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev 2013; (5): CD004744. Malouf R

2016 MJA Clinical Guidelines

152. Cochrane team criticises the ECDC experts' draft advice on oseltamivir use

efficacy and safety have not been established. Translated from Med Check-TIP (in Japanese) Mar. 06 ; 6 (63):3-7Page 4· MED CHECK - TIP April 2016/ Vol.2 No.4 New Products New Products (Reminyl) and rivastigmine (Rivastouch, Exelon Patch); and an NMDA receptor antagonist (NMDA antagonist), memantine (Memary) (Table). Cholinesterase inhibitors are expected to activate mental activities by increasing acetylcholine in the brain. Memantine is expected to exhibit the similar effect by inhibiting NMDA

2016 Med Check - The Informed Prescriber

153. Wakix - pitolisant. Narcolepsy

is involved in the trigger of HCl secretion and is partly controlled by H3R, specific studies were performed with an acetylcholine esterase inhibitor, rivastigmine, which is known to increase gastric acid secretion. Pitolisant at up to 10 mg/kg p.o did not induce gastric ulcer when given alone or in combination with rivastigmine. Since rivastigmine alone did not induce gastric ulcer in the experimental conditions of this assay, a conclusion on the lack of potentiation of rivastigmine’s effect on gastric (...) with rivastigmine enhanced the ability of both compound to increase extracellular acetylcholine levels. Some interactions were found with lisuride and ropinirole (D2 agonists used in the treatment of PD), but were assessed to be caused by PK interactions. 2.3.3. Pharmacokinetics In rats dosed with [ 14 C]-pitolisant the bioavailability was only 1.5% when unchanged pitolisant was considered and nearly 100% when total [ 14 C] was considered. This can be explained by an active first- Assessment report EMA/828546

2016 European Medicines Agency - EPARs

154. Diagnosis and Management of Dementia: Review. Full Text available with Trip Pro

, this includes an acetylcholinesterase inhibitor such as donepezil for mild to severe dementia, and memantine (used alone or as an add-on therapy) for moderate to severe dementia. Rivastigmine can be used to treat symptomatic Parkinson disease dementia.Alzheimer disease currently affects 5.8 million persons in the United States and is a common cause of dementia, which is usually accompanied by other neuropathology, often cerebrovascular disease such as brain infarcts. Causes of dementia can be diagnosed

2019 JAMA

156. Rivastigmine in Chinese patients with subcortical vascular dementia. (Abstract)

Rivastigmine in Chinese patients with subcortical vascular dementia. We explored the efficacy and tolerability of rivastigmine among Chinese patients with subcortical vascular dementia.Forty subjects were randomized to either placebo (n = 20) or rivastigmine (n = 20) in a double-blind 26-week trial. Outcome measures were cognition (mini-mental state examination, frontal assessment battery), neuropsychiatric inventory (NPI), instrumental activities of daily living, clinical dementia rating scale (...) , and adverse events.No statistical significant benefit could be observed in the active group in any of the efficacy measures. A trend favoring active group was observed only in the NPI subscore of irritability (p = 0.066) and aberrant motor behavior (p = 0.068). Withdrawal rate was 30% and 15% in the active and placebo group, respectively.Among Chinese subcortical vascular dementia patients, there was no apparent cognitive benefit associated with use of rivastigmine over the 6 months period. A trend

2011 Neuropsychiatric disease and treatment Controlled trial quality: uncertain

157. Low dose, short-term rivastigmine administration does not affect neurocognition in methamphetamine dependent individuals. (Abstract)

Low dose, short-term rivastigmine administration does not affect neurocognition in methamphetamine dependent individuals. Neurocognitive impairment is a well-documented consequence of methamphetamine addiction. Not surprising, methamphetamine-associated neurocognitive impairment has been identified as an important target of treatment. Thus, this study sought to determine whether rivastigmine, an acetylcholinesterase inhibitor and cognition enhancing agent, could improve neurocognitive (...) performance in a sample of long-term, high-dose methamphetamine addicts who were not seeking treatment at the time of enrollment in the study. This double-blind, placebo-controlled study evaluated whether a daily dose 0, 3, or 6 mg of rivastigmine, administered over six consecutive days, would enhance performance on measures of attention/information processing speed, episodic memory, and executive/frontal lobe functioning relative to test performance at baseline. The results revealed that rivastigmine did

2011 Pharmacology, biochemistry, and behavior

158. Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis. (Abstract)

Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis. Rivastigmine treatment is associated with significant improvements on the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) in patients with mild-to-moderate Alzheimer's disease (AD) and Parkinson's disease dementia (PDD). Both AD and PDD are purported to have different profiles of cognitive impairment, which may respond differentially to rivastigmine treatment (...) . This was a retrospective analysis of 3 randomized, double-blind, rivastigmine trial databases (Investigation of transDermal Exelon in ALzheimer's disease [IDEAL; AD], EXelon in PaRkinson's disEaSe dementia Study [EXPRESS; PDD], and Alzheimer's Disease with ENA 713 [ADENA; AD]). Factor analyses of the 11 baseline ADAS-cog items derived the same factors in the 2 diseases, that is, "memory" and "language". Rivastigmine-treated AD and PDD patients showed significant improvements (P < .0001 versus placebo) on both factors

2011 American journal of Alzheimer's disease and other dementias

159. A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease

A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01399125 Recruitment Status : Completed First Posted : July

2011 Clinical Trials

160. Rivastigmine in the Management of Delirium

Rivastigmine in the Management of Delirium Rivastigmine in the Management of Delirium - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Rivastigmine in the Management of Delirium (confuriv) The safety (...) Paris Study Details Study Description Go to Brief Summary: The aim of this study is to evaluate the efficacy of an anticholinesterase treatment in patients aged 75 and over, hospitalized with delirium. Study type : Interventional Study design: randomized, double-blind, placebo-controlled study during one month and a 11-month follow-up Condition or disease Intervention/treatment Phase Delirium Drug: Rivastigmine transdermal patch Drug: placebo patch Phase 3 Detailed Description: Delirium affects up

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>